| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 73846 |
CAS: 1639939-40-4，Mal-Val-Ala-PAB-PNP，马来酰亚胺-VAL-ALA-PAB-PNP |
124 |
WYQ |
2024-12-19 |
| 73847 |
Fmoc-VC-PAB-Duocarmycin SA， ADC试剂 |
96 |
kx |
2024-12-19 |
| 73848 |
Mal-PEG4-Val-Ala-PAB，可降解的ADC（抗体偶联药物）连接子 |
154 |
WYQ |
2024-12-19 |
| 73849 |
Mal-PEG1-Val-Cit-OH的介绍 |
125 |
zyl |
2024-12-19 |
| 73850 |
MC-vc-PAB-Monomethyl dolastatin10， ADC试剂 |
84 |
kx |
2024-12-19 |
| 73851 |
CAS: 1870916-87-2，Mal-Val-Ala-PAB，马来酰亚胺-缬氨酸-丙氨酸-对氨基苯甲酸 |
91 |
WYQ |
2024-12-19 |
| 73852 |
cas:2395887-69-9 Mal-PEG2-Val-Cit-PAB-PNP |
87 |
zyl |
2024-12-19 |
| 73853 |
SuO-Val-Cit-PAB-MMAE， ADC试剂 |
78 |
kx |
2024-12-19 |
| 73854 |
Mal-PEG4-Val-Ala-PAB-PNP的介绍 |
88 |
zyl |
2024-12-19 |
| 73855 |
CAS: 2348405-93-4，DBCO-PEG4-Val-Ala-PAB-PNP |
65 |
WYQ |
2024-12-19 |
| 73856 |
CAS: 2348405-92-3，DBCO-PEG4-Val-Ala-PAB |
79 |
WYQ |
2024-12-19 |
| 73857 |
cas:2112738-13-1 Mal-amido-PEG2-Val-Cit-PAB-PNP |
80 |
zyl |
2024-12-19 |
| 73858 |
Azido-PEG4-Val-Ala-PAB，分子式：C29H48N8O9 |
69 |
WYQ |
2024-12-19 |
| 73859 |
cas:2055896-86-9，MC-Val-Cit-PAB-tubulysin5a ， ADC试剂 |
87 |
kx |
2024-12-19 |
| 73860 |
Azido-PEG8-Val-Cit-PAB-PNP |
65 |
zyl |
2024-12-19 |
| 73861 |
cas:2055896-83-6，MC-Val-Cit-PAB-carfilzomib ， ADC试剂 |
109 |
kx |
2024-12-19 |
| 73862 |
MAL-di-EG-Val-Cit-PAB-MMAF， ADC试剂 |
81 |
kx |
2024-12-19 |
| 73863 |
cas:2353409-45-5 endo BCN-PEG3-VC-PFP Ester |
91 |
zyl |
2024-12-19 |
| 73864 |
Hydrazone-doxorubicin， ADC试剂 |
162 |
kx |
2024-12-19 |
| 73865 |
DBCO-C4-Val-Cit-PABC-PNP |
72 |
zyl |
2024-12-19 |
| 73866 |
cas:644981-35-1 Val-Cit-PAB-MMAE |
79 |
zyl |
2024-12-19 |
| 73867 |
cas:170908-81-3，DOTA-NHS ester ，1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸 1-(2,5-二氧代-1-吡咯烷基)酯 |
70 |
kx |
2024-12-19 |
| 73868 |
endo-BCN-PEG4-Val-Cit-PAB-MMAE的介绍 |
79 |
zyl |
2024-12-19 |
| 73869 |
cas:2259318-50-6，MA-PEG4-VA-PBD ， ADC试剂 |
92 |
kx |
2024-12-19 |
| 73870 |
CAS: 2259318-55-1 - DBCO-(PEG2-VC-PAB-MMAE)2 |
61 |
WYQ |
2024-12-19 |
| 73871 |
CAS: 2768446-73-5，DBCO-Val-Cit-PAB-MMAE |
73 |
WYQ |
2024-12-19 |
| 73872 |
MC-vc-PAB-C6-a-amanitin， ADC试剂 |
66 |
kx |
2024-12-19 |
| 73873 |
cas:663598-98-9，2,5-dioxopyrrolidin-1-yl 4-methyl-4-((5-nitropyridin-2-yl)disulfanyl)pentanoate，ADC定制 |
87 |
wyh |
2024-12-19 |
| 73874 |
cas:2873452-49-2 MC-EVCit-PAB-MMAE |
84 |
zyl |
2024-12-19 |
| 73875 |
2,5-dioxopyrrolidin-1-yl 3-methyl-3-(pyridin-2-yldisulfanyl)butanoate，ADC定制 |
92 |
wyh |
2024-12-19 |
| 73876 |
cas:159857-70-2 MC-Val-Cit-Doxorubicin |
114 |
zyl |
2024-12-19 |
| 73877 |
Gly3-vc-PAB-MMAE， ADC试剂 |
93 |
kx |
2024-12-19 |
| 73878 |
CAS: 1869126-64-6， Azido-PEG4-Val-Cit-PAB-MMAE |
75 |
WYQ |
2024-12-19 |
| 73879 |
cas:2353409-54-6 ， Mal-amido-PEG8-Val-Gly，ADC定制 |
92 |
wyh |
2024-12-19 |
| 73880 |
Azido-PEG4-Val-Ala-PAB-PNP |
92 |
zyl |
2024-12-19 |
| 73881 |
NOTA-(NGR)2 NOTA偶联NGR二聚体 |
76 |
h |
2024-12-19 |
| 73882 |
1-(2,5-dioxopyrrolidin-1-yloxy)-4-((5-nitropyridin-2-yl)disulfanyl)-1-oxobutane-2-sulfonic acid，ADC定制 |
84 |
wyh |
2024-12-19 |
| 73883 |
CAS: 1343476-44-7，Val-Ala-PAB-OH |
71 |
WYQ |
2024-12-19 |
| 73884 |
MC-PBD， ADC试剂 |
84 |
kx |
2024-12-19 |
| 73885 |
Mal-Val-Ala-PAB的介绍 |
82 |
zyl |
2024-12-19 |
| 73886 |
DOTA-K-A9 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)结合肽A9 |
73 |
h |
2024-12-19 |
| 73887 |
Azide-PEG3-Val-Cit-PAB-MMAF，叠氮-三聚乙二醇-Val-Cit-PAB-MMAF |
73 |
WYQ |
2024-12-19 |
| 73888 |
Arm-DOTA-B72.3 |
72 |
h |
2024-12-19 |
| 73889 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
88 |
zyl |
2024-12-19 |
| 73890 |
(Lys(DOTA)4)BVD15 DOTA偶联神经肽Y(NPY)类似物 |
122 |
h |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询